A randomized control trial comparing peginterferon-α-2a versus observation after stopping tyrosine kinase inhibitor in chronic myeloid leukemia with deep molecular response for at least two years
Background: There is much advancement in treatment of chronic myeloid leukemia (CML) since the approval of first tyrosine kinase inhibitor (TKI), imatinib, by US FDA in 2001. One of them is definitely the concept of stopping TKI, starting at the CML patients who have achieved deep molecular resp...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Conference or Workshop Item |
| Language: | English |
| Published: |
2016
|
| Subjects: | |
| Online Access: | http://ir.unimas.my/id/eprint/12285/1/A%20RANDOMIZED%20CONTROL%20TRIAL%20COMPARING%20PEGINTERFERON-%CE%B1-2a.pdf http://ir.unimas.my/id/eprint/12285/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|